N/A N=100 APT™ T3X on the COVID-19 Contamination Rate
COVID-19
Primary: COVID-19 Contamination Rate. — 2; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=371 Peer Led Asthma Self Management for Adolescents: PLASMA
Asthma
Primary: The Pediatric Asthma Quality of Life Questionnaire (PAQOL) — 5.58; 5.93; 6.49 score on a scale — p=.043
N/A N=40 Mirthful Laughter and Muscle Soreness / Pain
Pain
Primary: Peak Force of Pain Tolerance Measurement — 2; 21 N
Phase 1 N=18 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers
Hepatic Impairment · Healthy Participants
Primary: Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours (AUC24) for PF-06651600 — 454.5; 383.6 nanogram*hour per milliliter (ng*hr/mL)
Phase 2 N=110 Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
Melanoma
Primary: Rate of Relapse-free Survival at 18 Months — 29; 28; 27; 26 Participants
Phase 2 N=41 Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
Breast Cancer
Primary: Three-year Relapse-free Survival — 61.5; 77.8 percentage of participants
N/A N=4 Convection Enhanced Delivery of CSF in DBS for Parkinson's
Parkinson Disease
Primary: Number of Participants With Adverse Events That Are Related to Treatment — 2 Participants
N/A N=319 Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization
Cardiovascular Diseases · Coronary Disease · Heart Failure
Primary: Survival Free of Cardiac Hospitalization
Phase 2 N=102 E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Phase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT) — 1; 2 Participants
Phase 2 N=45 CTx-1301 Comparative Bioavailability Study
ADHD
Primary: Cmax — 3138.41; 2874.52; 0.92; 23884.13 pg/mL
Phase 2 N=60 Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
Anemia · Dialysis Dependent Chronic Kidney Disease
Primary: Mean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period — -0.28; 0.08; 0.41; -1.48 grams per deciliter (g/dL) — p=0.0004
Phase 3 N=10 Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome
Short Bowel Syndrome
Primary: Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early…
Phase 2 N=51 Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
Anemia · Non-dialysis Dependent Chronic Kidney Disease
Primary: Mean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period — 0.43; 1.13; 1.62; -0.47 grams per deciliter (g/dL) — p=0.0045
N/A N=14 To Compare Free Gingival Grafts and Connective Tissue Grafts Around Implants With Lack of Keratinized Mucosa
Dental Implants · Alveolar Mucosa
Primary: The Increase in Keratinized Mucosa (in mm) Between the Two Grafts — 3.29; 1.29 mm
Phase 2 N=15 Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
Leber Congenital Amaurosis
Primary: Overall Safety of Adeno-Associated Virus Vector (AAV-OPTIRPE65) - Number of Participants With a Safety Event — 0; 0; 1; 0 Participants